Stock Analysis
Black Diamond Therapeutics, Inc. (BDTX) Stock Analysis
Black Diamond Therapeutics, Inc. (BDTX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Black Diamond Therapeutics, Inc. (BDTX) currently has an AIQ Score of 35/100, indicating a bearish setup. Momentum is the strongest factor at 43/100. Quality is the weakest current factor at 27/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
BDTX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $1.78 |
| AIQ Score | 35/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Neutral |
| Market Cap | $116.9M |
| P/E Ratio (TTM) | -2.76 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | -$0.17 |
| Revenue (quarter ended 2026-06-30) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 3.29 |
| Volume | 520.16K |
| 52-week range | $1.60-$4.94 |
| RSI 14 | 51.3 |
| 50-Day SMA | $1.96 |
| 200-Day SMA | $2.20 |
| Analyst Price Target | $8.00 |
| Next Earnings | Nov 5, 2026 |
BDTXBlack Diamond Therapeutics, Inc.
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum43
- Value—
- Quality27
- Risk resilience37
- Sentiment—
BDTX Stock Analysis Summary
Black Diamond Therapeutics, Inc. (BDTX) currently has an AIQ Score of 35/100, indicating a bearish setup. Momentum is the strongest factor at 43/100. Quality is the weakest current factor at 27/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, BDTX has AIQ Score of 35/100 with Momentum base of 43/100 and fading Quality at 27/100. Wait for component alignment before adding exposure.
Healthcare · -4.30% stock move · BDTX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is BDTX Bullish or Bearish Right Now?
BDTX currently has a bearish overall setup. Momentum is the strongest factor at 43/100, while Quality is weakest at 27/100. The current evidence suggests a defensive setup.
- - Analyst target implies +349.44% upside from the latest quote.
- - Momentum is weak at 43/100.
- - Risk Resilience is weak at 37/100.
- - Price is -15.32% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (18 vs 17).
Current Consensus
BDTX's Technical Analysis Consensus is currently Neutral, with 17 buy, 10 neutral, and 18 sell votes. BDTX's 14-day RSI is 51.3, which places the stock in a neutral momentum range. BDTX's beta is 3.29, indicating greater market sensitivity than the broad market.
What Changed in BDTX?
The largest recent change in BDTX is Momentum moving down by 21.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the BDTX Outlook?
The current bearish outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
BDTX Decision Framework
Public evidence layers, setup checks, and risk context for Black Diamond Therapeutics, Inc..
Black Diamond Therapeutics, Inc. (BDTX) Stock Analysis
Black Diamond Therapeutics, Inc. has an AIQ Score of 35/100 in a Defensive regime. Momentum is strongest at 43/100. Beta is 3.33, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | BDTX is in a Defensive AIQ regime with score 35/100. |
| Signal Conflict | The primary conflict is that momentum leads at 43/100 while quality lags at 27/100. |
| Factor Evidence | Momentum 43/100 · Quality 27/100 · Risk 37/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 43/100.
Momentum is 43/100 and RSI (14) is 51.3.
BDTX is in a Defensive regime at 35/100.
Risk factor is 37/100 with beta 3.33 and annual volatility 81.98%.
Current conflict: momentum leads at 43/100 while quality lags at 27/100.
BDTX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
BDTX Fundamentals
BDTX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
BDTX Technical Analysis
BDTX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
BDTX Stock Catalysts
Track BDTX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
BDTX Dividend Analysis
BDTX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
BDTX Financial Data
BDTX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
BDTX Risk Analysis
BDTX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
BDTX Stock News
BDTX stock news, market tone, recent headlines, and catalyst context.
BDTX vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: BDTX · BEAM · CRSP · DNLI · DTIL. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| BDTX Current stock | 35/100 | — | 43/100 | 37/100 | -0.49 | 81.98% | Current |
| BEAM Beam Therapeutics | 45/100 | 34/100 | 74/100 | 36/100 | 0.51 | 71.71% | BDTX vs BEAM |
| CRSP CRISPR Therapeutics | 36/100 | 34/100 | 52/100 | 40/100 | -0.03 | 57.59% | BDTX vs CRSP |
| DNLI Denali Therapeutics | 40/100 | 34/100 | 41/100 | 67/100 | 0.52 | 55.12% | BDTX vs DNLI |
| DTIL Precision BioSciences | 58/100 | 60/100 | 70/100 | 51/100 | 0.11 | 69.22% | BDTX vs DTIL |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 29, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching BDTX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for BDTX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
BDTX Stock FAQ
What is BDTX stock price today?
Black Diamond Therapeutics, Inc.'s current stock price is $1.78. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is BDTX bullish or bearish right now?
BDTX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is BDTX's market cap?
BDTX's market cap is $116.9M based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is BDTX's current P/E ratio?
BDTX's current P/E ratio is -2.76 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is BDTX's RSI?
BDTX's 14-day RSI is 51.3 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is BDTX above its 50-day and 200-day moving averages?
BDTX is -4.93% from its 50-day SMA and -15.32% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is BDTX's next earnings date?
BDTX's next earnings date is currently listed as Nov 5, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does BDTX pay a dividend?
BDTX's dividend yield is 0.00% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.